Polymyalgia Rheumatica Market

DelveInsight’s ‘Polymyalgia Rheumatica (PMR)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Polymyalgia Rheumatica (PMR), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Polymyalgia Rheumatica (PMR) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted PMR symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Polymyalgia Rheumatica (PMR) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Polymyalgia Rheumatica (PMR) Disease Understanding and Treatment Algorithm

Polymyalgia Rheumatica (PMR) Overview

Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic condition in people aged over 50 years after rheumatoid arthritis (RA). PMR can occur independently or in association with giant cell arteritis (GCA). Giant cell arteritis is the most common primary vasculitis in this age group.


PMR is a rare inflammatory disease characterized by muscle pain (myalgia), stiffness, and additional generalized systemic symptoms such as fatigue, low-grade fever, and/or a general feeling of ill health (malaise). It can be a relatively benign condition that is extremely responsive to treatment. In some rare cases, permanent muscle weakness, degeneration and loss (atrophy) of muscle mass, and disability may occur.


The cause of PMR is uncertain, but it is believed to be an autoimmune disease in which the body’s immune system attacks healthy tissues. Genetic and environmental factors (such as infections) are thought to play important roles. Because it is rare in people under age 50, its cause could be linked to the aging process.


he diagnosis of PMR may be confirmed by a thorough clinical examination, including detailed patient history and specialized blood testing that demonstrates an abnormally elevated sedimentation rate. Other substances in the blood, such as serum albumin, globulins, and fibrinogen, may also be elevated.


PMR treatment focuses on reducing pain and inflammation and easing stiffness, achiness, fatigue, and fever. Treatment includes anti-inflammatory medication and exercise. Corticosteroids are powerful anti-inflammatory drugs that help reduce inflammation and relieve stiffness and pain. They are the mainstay of PMR treatment. The dosage for PMR is low, and symptoms will improve quickly with treatment. The dosage will be lowered further once symptoms improve. Occasionally, mild PMR cases are treated with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, to ease symptoms.


Both exercise and rest play important roles in PMR treatment. Regular exercise is essential for maintaining joint flexibility, muscle strength, and function. Good forms of exercise include walking, riding a stationary bicycle, and exercising in a pool.


Polymyalgia Rheumatica (PMR) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Polymyalgia Rheumatica (PMR) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Polymyalgia Rheumatica (PMR) market report gives a thorough understanding of PMR symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides PMR symptoms of treatment algorithms and treatment guidelines for PMR symptoms in the US, Europe, and Japan.

Polymyalgia Rheumatica (PMR) Epidemiology

The epidemiology division’s Polymyalgia Rheumatica (PMR) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Polymyalgia Rheumatica (PMR) epidemiology segmented as the Prevalence of Polymyalgia Rheumatica (PMR), Prevalence of Polymyalgia Rheumatica (PMR) based on Clinical Manifestation, Gender-specific cases of Polymyalgia Rheumatica (PMR), Diagnosed cases GCA in PMR. The report includes the prevalent PMR scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Polymyalgia Rheumatica (PMR) Epidemiology

The epidemiology segment also provides the Polymyalgia Rheumatica (PMR) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total 7MM prevalent cases of Polymyalgia Rheumatica (PMR) were 1,708,823 in 2020.

Polymyalgia Rheumatica (PMR) Drug Chapters

The drug chapter segment of the Polymyalgia Rheumatica (PMR) report encloses the detailed analysis of PMR marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Polymyalgia Rheumatica (PMR) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Its treatment focuses on reducing pain and inflammation and easing stiffness, achiness, fatigue, and fever. Guidelines have been set forth regarding the optimal PMR classification and management, but they must be taken in the context of the situation and cannot be used in every circumstance. Treatment includes anti-inflammatory medication and exercise and usually involves medications to help ease your signs and symptoms. Relapses are common. However, with the proper treatment, symptoms can improve in as little as 24–48 h.

Products detail in the report…


Polymyalgia Rheumatica (PMR) Emerging Drugs

Tocilizumab is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody of the immunoglobulin IgG1κ (gamma 1, kappa) subclass with a typical H2L2 polypeptide structure. It is a medication designed to specifically block the cytokine interleukin-6, a protein involved in various inflammatory disorders. Studies have shown that patients with PMR have elevated interleukin-6 levels; thus, the drug has been tested for PMR.

Products detail in the report…

Polymyalgia Rheumatica (PMR) Market Outlook

The Polymyalgia Rheumatica (PMR) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Polymyalgia Rheumatica (PMR) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.


This segment gives a thorough detail of Polymyalgia Rheumatica (PMR) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Polymyalgia Rheumatica (PMR) market in 7MM is expected to change in the study period 2018–2030.


Key Findings

This section includes a glimpse of the Polymyalgia Rheumatica (PMR) market in 7MM. The market size of PMR in the seven major markets was found to be USD 2,893.57 million in 2020, and the market is estimated to increase at a CAGR of 13.60% for the study period (2018–2030).


The United States Market Outlook

This section provides a total of Polymyalgia Rheumatica (PMR) market size and market size by therapies in the United States.

The United States accounts for the highest PMR market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Polymyalgia Rheumatica (PMR) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Polymyalgia Rheumatica (PMR) market size and market size by therapies in Japan are also mentioned.

Polymyalgia Rheumatica (PMR) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Polymyalgia Rheumatica (PMR) market uptake by drugs, patient uptake by therapies, and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Polymyalgia Rheumatica (PMR) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Polymyalgia Rheumatica (PMR) key players involved in developing targeted therapeutics.


Major players include Tocilizumab (Roche Chugai), Abatacept (Bristol-Myers Squibb), and Baricitinib (Eli Lilly), being assessed as potential therapies to be available in the market in the coming future.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Polymyalgia Rheumatica (PMR) emerging therapies.

Reimbursement Scenario in Polymyalgia Rheumatica (PMR)

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Polymyalgia Rheumatica (PMR) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Polymyalgia Rheumatica (PMR) market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Polymyalgia Rheumatica (PMR) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Polymyalagia Rheumatica (PMR), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Polymyalgia Rheumatica (PMR) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Polymyalgia Rheumatica (PMR) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Polymyalgia Rheumatica (PMR) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Polymyalgia Rheumatica (PMR) market

Report Highlights

  • In the coming years, Polymyalgia Rheumatica (PMR) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Polymyalgia Rheumatica (PMR) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for PMR. The launch of emerging therapies will significantly impact the Polymyalgia Rheumatica (PMR) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for PMR.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Polymyalgia Rheumatica (PMR) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Polymyalgia Rheumatica (PMR) Pipeline Analysis
  • Polymyalgia Rheumatica (PMR) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Polymyalgia Rheumatica (PMR) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Polymyalgia Rheumatica (PMR) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Polymyalgia Rheumatica (PMR) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Polymyalgia Rheumatica (PMR) Market share (%) distribution in 2020, and how would it look in 2030?
  • What would be the Polymyalgia Rheumatica (PMR) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the market’s key findings across 7MM, and which country will have the largest Polymyalgia Rheumatica (PMR) market Size during the forecast period (2021–2030)?
  • At what CAGR, the Polymyalgia Rheumatica (PMR) market is expected to grow by 7MM during the forecast period (2021–2030)?
  • What would be the Polymyalgia Rheumatica (PMR) market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Polymyalgia Rheumatica (PMR) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Polymyalgia Rheumatica (PMR)?
  • What is the historical Polymyalgia Rheumatica (PMR) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Polymyalgia Rheumatica (PMR) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Polymyalgia Rheumatica (PMR)?
  • Out of all 7MM countries, which country would have the highest prevalent polymyalgia Rheumatica (PMR) population during the forecast period (2021–2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Polymyalgia Rheumatica (PMR)?
  • What are the current treatment guidelines for treating Polymyalgia Rheumatica (PMR) in the USA, Europe, and Japan?
  • What are the Polymyalgia Rheumatica (PMR) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Polymyalgia Rheumatica (PMR)?
  • How many therapies are developed by each company for the treatment of Polymyalgia Rheumatica (PMR)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Polymyalgia Rheumatica (PMR)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polymyalgia Rheumatica (PMR) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Polymyalgia Rheumatica (PMR) and their status?
  • What are the key designations that have been granted for the emerging therapies for Polymyalgia Rheumatica (PMR)?
  • What are the global historical and forecasted markets of Polymyalgia Rheumatica (PMR)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Polymyalgia Rheumatica (PMR) market
  • To understand the future market competition in the Polymyalgia Rheumatica (PMR) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Polymyalgia Rheumatica (PMR) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Polymyalgia Rheumatica (PMR) market
  • To understand the future market competition in the Polymyalgia Rheumatica (PMR) market

1. Key Insights

2. Report Introduction

3. Polymyalgia Rheumatica Market Overview at a Glance

3.1. Market Share (%) Distribution of Polymyalgia Rheumatica in 2018

3.2. Market Share (%) Distribution of Polymyalgia Rheumatica in 2030

4. Executive Summary of Polymyalgia Rheumatica

5. Disease Background and Overview

5.1. Introduction

5.2. Symptoms

5.3. Etiology

5.4. Pathogenesis

5.5. Clinical Manifestation

5.6. Diagnosis

5.6.1. Classification Criteria

6. Management and Treatment of PMR

6.1. EULAR/ACR Recommendation

6.2. Treatment Algorithm

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalent Patient Population of Polymyalgia Rheumatica

7.3. Epidemiology of Polymyalgia Rheumatica

7.4. The United States

7.4.1. Prevalence of Polymyalgia Rheumatica in the United States

7.4.2. Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United States

7.4.3. Gender-specific Prevalence of Polymyalgia Rheumatic in the United States

7.4.4. Diagnosed Cases of GCA in PMR in the United States

7.5. EU5

7.5.1. Germany

7.5.2. France

7.5.3. Italy

7.5.4. Spain

7.5.5. United Kingdom

7.6. Japan

7.6.1. Prevalence of Polymyalgia Rheumatica in Japan

7.6.2. Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Japan

7.6.3. Gender-specific Prevalence of Polymyalgia Rheumatic in Japan

7.6.4. Diagnosed Cases of GCA in PMR in Japan

8. Organizations contributing towards Polymyalgia Rheumatica

9. Patient Journey

10. Case Reports

11. Emerging Therapies

11.1. Tocilizumab: Roche Chugai

11.1.1. Drug Description

11.1.2. Other Development Information

11.1.3. Clinical Development

11.1.4. Clinical Trials Information

11.1.5. Safety and Efficacy

11.1.6. Product Profile

11.2. Abatacept: Bristol-Myers Squibb

11.2.1. Drug Description

11.2.2. Other Development Information

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Product Profile

11.3. Baricitinib: Eli Lilly

11.3.1. Drug Description

11.3.2. Other Development Information

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

12. Polymyalgia Rheumatica: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Polymyalgia Rheumatica in 7MM

12.3. Market Size of Polymyalgia Rheumatica by Therapies

13. Market Outlook

13.1. United States Market Size

13.1.1. Total Market Size of Polymyalgia Rheumatica in the United States

13.1.2. Market Size of Polymyalgia Rheumatica by Therapies in the United States

13.2. EU-5 Market Size

13.2.1. Germany

13.2.2. France

13.2.3. Italy

13.2.4. Spain

13.2.5. United Kingdom

13.3. Japan

13.3.1. Total Market size of Polymyalgia Rheumatica in Japan

13.3.2. Market Size of Polymyalgia Rheumatica by Therapies in Japan

14. KOL Views

15. Market Access

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Unmet Needs

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of PMR, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Summary of classification criteria for polymyalgia rheumatica (PMR)

Table 3: PMR classification criteria scoring algorithm by EULAR/ACR

Table 4: Total Diagnosed Prevalent Patient Population of Polymyalgia Rheumatica in 7MM in 000’s (2018–2030)

Table 5: Prevalence of Polymyalgia Rheumatica in the United States (2018–2030)

Table 6: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United States (2018–2030)

Table 7: Gender-specific Prevalence of Polymyalgia Rheumatic in the United States (2018–2030)

Table 8: Diagnosed Cases of GCA in PMR in the United States (2018–2030)

Table 9: Prevalence of Polymyalgia Rheumatica in Germany (2018–2030)

Table 10: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Germany (2018–2030)

Table 11: Gender-specific Prevalence of Polymyalgia Rheumatic in Germany (2018–2030)

Table 12: Diagnosed Cases of GCA in PMR in Germany (2018–2030)

Table 13: Prevalence of Polymyalgia Rheumatica in (2018–2030)

Table 14: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in France (2018–2030)

Table 15: Gender-specific Prevalence of Polymyalgia Rheumatic in France (2018–2030)

Table 16: Diagnosed Cases of GCA in PMR in France (2018–2030)

Table 17: Prevalence of Polymyalgia Rheumatica in Italy (2018–2030)

Table 18: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Italy (2018–2030)

Table 19: Gender-specific Prevalence of Polymyalgia Rheumatic in Italy (2018–2030)

Table 20: Diagnosed Cases of GCA in PMR in Italy (2018–2030)

Table 21: Prevalence of Polymyalgia Rheumatica in Spain (2018–2030)

Table 22: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Spain (2018–2030)

Table 23: Gender-specific Prevalence of Polymyalgia Rheumatic in Spain (2018–2030)

Table 24: Diagnosed Cases of GCA in PMR in Spain (2018–2030)

Table 25: Prevalence of Polymyalgia Rheumatica in the United Kingdom (2018–2030)

Table 26: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United Kingdom (2018–2030)

Table 27: Gender-specific Prevalence of Polymyalgia Rheumatic in the United Kingdom (2018–2030)

Table 28: Diagnosed Cases of GCA in PMR in the United Kingdom (2018–2030)

Table 29: Prevalence of Polymyalgia Rheumatica in Japan (2018–2030)

Table 30: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Japan (2018–2030)

Table 31: Gender-specific Prevalence of Polymyalgia Rheumatic in Japan (2018–2030)

Table 32: Diagnosed Cases of GCA in PMR in Japan (2018–2030)

Table 33: Organizations contributing towards Polymyalgia Rheumatica

Table 34: NeuroSTAT, Clinical Trial Description, 2021

Table 35: Abatacept, Clinical Trial Description, 2021

Table 36: Baricitinib, Clinical Trial Description, 2021

Table 37: Seven Major Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Table 38: Seven Major Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Table 39: United States Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Table 40: United States Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Table 41: Germany Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Table 42: Germany Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Table 43: France Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Table 44: France Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Table 45: Italy Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Table 46: Italy Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Table 47: Spain Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Table 48: Spain Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Table 49: United Kingdom Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Table 50: United Kingdom Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Table 51: Japan Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Table 52: Japan Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Pathogenic mechanisms in polymyalgia rheumatica (PMR)

Figure 2: Distribution of symptoms

Figure 3: Algorithm based on the 2015 EULAR/ACR recommendations for the management of polymyalgia rheumatica (PMR)

Figure 4: Total Diagnosed Prevalent Population of Polymyalgia Rheumatica in 7MM (2018–2030)

Figure 5: Prevalence of Polymyalgia Rheumatica in the United States (2018–2030)

Figure 6: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United States (2018–2030)

Figure 7: Gender-specific Prevalence of Polymyalgia Rheumatic in the United States (2018–2030)

Figure 8: Diagnosed Cases of GCA in PMR in the United States (2018–2030)

Figure 9: Prevalence of Polymyalgia Rheumatica in Germany (2018–2030)

Figure 10: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Germany (2018–2030)

Figure 11: Gender-specific Prevalence of Polymyalgia Rheumatic in Germany (2018–2030)

Figure 12: Diagnosed Cases of GCA in PMR in Germany (2018–2030)

Figure 13: Prevalence of Polymyalgia Rheumatica in France (2018–2030)

Figure 14: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in France (2018–2030)

Figure 15: Gender-specific Prevalence of Polymyalgia Rheumatic in France (2018–2030)

Figure 16: Diagnosed Cases of GCA in PMR in France (2018–2030)

Figure 17: Prevalence of Polymyalgia Rheumatica in Italy (2018–2030)

Figure 18: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Italy (2018–2030)

Figure 19: Gender-specific Prevalence of Polymyalgia Rheumatic in Italy (2018–2030)

Figure 20: Diagnosed Cases of GCA in PMR in Italy (2018–2030)

Figure 21: Prevalence of Polymyalgia Rheumatica in Spain (2018–2030)

Figure 22: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Spain (2018–2030)

Figure 23: Gender-specific Prevalence of Polymyalgia Rheumatic in Spain (2018–2030)

Figure 24: Diagnosed Cases of GCA in PMR in Spain (2018–2030)

Figure 25: Prevalence of Polymyalgia Rheumatica in the United Kingdom (2018–2030)

Figure 26: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United Kingdom (2018–2030)

Figure 27: Gender-specific Prevalence of Polymyalgia Rheumatic in the United Kingdom (2018–2030)

Figure 28: Diagnosed Cases of GCA in PMR in the United Kingdom (2018–2030)

Figure 29: Prevalence of Polymyalgia Rheumatica in Japan (2018–2030)

Figure 30: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Japan (2018–2030)

Figure 31: Gender-specific Prevalence of Polymyalgia Rheumatic in Japan (2018–2030)

Figure 32: Diagnosed Cases of GCA in PMR in Japan (2018–2030)

Figure 33: 7 Major Market Size of Polymyalgia Rheumatica in USD Million (2018–2030)

Figure 34: 7 Major Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Figure 35: Market Size of Polymyalgia Rheumatica in the United States, USD Million (2018–2030)

Figure 36: The United States Market Size of Polymyalgia Rheumatica by Therapies in USD Million

Figure 37: Market Size of Polymyalgia Rheumatica in Germany, USD Million (2018–2030)

Figure 38: The Germany Market Size of Polymyalgia Rheumatica by Therapies in USD Million

Figure 39: Market Size of Polymyalgia Rheumatica in France, USD Million (2018–2030)

Figure 40: The France Market Size of Polymyalgia Rheumatica by Therapies in USD Million

Figure 41: Market Size of Polymyalgia Rheumatica in Italy, USD Million (2018–2030)

Figure 42: The Italy Market Size of Polymyalgia Rheumatica by Therapies in USD Million

Figure 43: Market Size of Polymyalgia Rheumatica in Spain, USD Million (2018–2030)

Figure 44: The Spain Market Size of Polymyalgia Rheumatica by Therapies in USD Million

Figure 45: Market Size of Polymyalgia Rheumatica in the United Kingdom, USD Million (2018–2030)

Figure 46: The United Kingdom Market Size of Polymyalgia Rheumatica by Therapies in USD Million

Figure 47: Market Size of Polymyalgia Rheumatica in Japan, USD Million (2018–2030)

Figure 48:The Japan Market Size of Polymyalgia Rheumatica by Therapies in USD Million (2018–2030)

Roche Chugai

Bristol-Myers Squibb

Eli Lilly

  • Tags:
  • Polymyalgia Rheumatica Market

Forward to Friend

Need A Quote